What about the dumbasses who don’t know the difference between “you’re” and “your”?
anonymous
Guest
anonymous
Guest
If you’re still here, then your career path is a disaster. Hope your previous experience and relationships can get you out of this mess. If you’re a male rep, this job is demasculating. If you’re a hot young female rep then you can rebound. As far as me, this was my last pharma job and it will never end up on my resume, thankful i doubledipped so my resume will never list the worst contract in the history of pharma. Worst low pay in hyper inflation and no samples. Nightmare!
You must feel proud of what you did. Hope payroll takes a look at this. Better yet, I’ll send payroll an email on Monday alerting them of a thief at the company stealing time. With technology and a look through ADP, should not be too hard to find you. And if they don’t, karma will deal with you.
anonymous
Guest
anonymous
Guest
Bonus payout update?
They must have potential payout dates on a “spin the wheel” game.
Wherever it lands, that’s the date. Or pin the tail on Phil game And wa-lah, there we have it.
They must have potential payout dates on a “spin the wheel” game.
Wherever it lands, that’s the date. Or pin the tail on Phil game And wa-lah, there we have it.
anonymous
Guest
anonymous
Guest
Contact says they can take 90 days to pay. Idorsia is holding up the bonus,not syneos. It will be end of July, first of August.
anonymous
Guest
anonymous
Guest
Contact says they can take 90 days to pay. Idorsia is holding up the bonus,not syneos. It will be end of July, first of August.
How do you know this is Idorsia holding out?
anonymous
Guest
anonymous
Guest
After 3.5 months of be strung along and the final candidate I was told 3 days after my final interview that an internal transferred occurred. THEN I saw an opening 45min from where I live. The hiring manager told me I would still be a candidate but of course interviewing still for it. I was then told last week nope went with another candidate. I told the recruiter after to never recommend roles for this company to me again. The hiring manager literally told me via email back in May “I’m hoping this works out so we can get you on board over here” when the roles had been pushed back 4-5 weeks which was really 6-7 weeks. I waited patiently. The hiring manager was always communicating with me except when I wasn’t offered the role when he himself said he would let me know either way. This company is one of the worst I’ve had to interview for. Everything happens for a reason.
anonymous
Guest
anonymous
Guest
Sorry to hear about your experience.
Layoffs happened in June along with collapsing territories that were vacant.
Last I heard, they are still in the process of collapsing territories of reps that resigned. Which is probably why you didn’t get the job.
National realignments happened July 1. It’s probably still messy behind the scenes.
We also haven’t been paid IC since trimester ended April.
You dodged a bullet
Layoffs happened in June along with collapsing territories that were vacant.
Last I heard, they are still in the process of collapsing territories of reps that resigned. Which is probably why you didn’t get the job.
National realignments happened July 1. It’s probably still messy behind the scenes.
We also haven’t been paid IC since trimester ended April.
You dodged a bullet
anonymous
Guest
anonymous
Guest
You not getting this opportunity is a huge blessing in disguise. 8:10 wld probably agree. This is single-handedly one of the worst companies in all of pharmaceuticals. Count yourself lucky. Most people here are looking for other opportunities as the misery is real.
anonymous
Guest
anonymous
Guest
8/10 or 4:1, moronYou not getting this opportunity is a huge blessing in disguise. 8:10 wld probably agree. This is single-handedly one of the worst companies in all of pharmaceuticals. Count yourself lucky. Most people here are looking for other opportunities as the misery is real.
anonymous
Guest
anonymous
Guest
8/10 or 4:1, moron
8:10= 4 : 5 , not 4:1. Seems to me you’re the elementary minded soul, probably in exponentially more ways than just math.
8:10 also means 8 out of 10 individuals.
Or, it could mean 4 out of 5. But NOT 4:1
Either way, you are wrong.
Go back to selling your 35mg Quviviq. That’s your mentality.
anonymous
Guest
anonymous
Guest
I pray to false sky god that they keep me, don't want new job, not now beloved nephew!
anonymous
Guest
anonymous
Guest
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
Release
July 20, 2023
Ad hoc announcement pursuant to Art. 53 LR
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
Allschwil, Switzerland – July 20, 2023
Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex- China) region (“Territory”), including assignment of PIVLAZ (clazosentan) and license rights to daridorexant in those territories, to Sosei Group Corporation (TSE: 4565; ‘Sosei Heptares’) for a total consideration of CHF 400 million.
Jean-Paul Clozel, Chief Executive Officer of Idorsia, commented:
“Dr Satoshi Tanaka and his team in Idorsia Japan have consistently demonstrated their ability to deliver high-quality clinical development studies, most recently reporting positive Phase 3 results with daridorexant. They also developed, registered, and successfully brought PIVLAZ to a specialty market, serving over 5’000 patients with a rare form of stroke in the first year alone. The excellence displayed by the organization has been recognized by Sosei, hence a deal that creates value for both companies. I’m particularly happy that we are maintaining our relationships to the team and our ability to reach patients in the territory with our pipeline products.”
Chris Cargill, President, and Chief Executive Officer of Sosei Heptares, commented:
“We have patiently and diligently been searching for the right opportunity to accelerate our mission to deliver life-changing new medicines to patients. This transaction with Idorsia is truly transformational and achieves one of our key strategic objectives, establishing Sosei Heptares as a fully integrated Japan-focused pharmaceutical business, with growing commercial sales and an expected new product launch next year. The addition of a highly experienced clinical development and entrepreneurial commercial team in Japan led by Dr Satoshi Tanaka, one of the country’s most successful drug developers in recent times, fast-tracks our vision to become one of Japan’s global biopharmaceutical champions.”
About the transaction
The transaction includes the acquisition by Sosei Heptares of Idorsia’s affiliates in Japan and South Korea, the assignment of the license for PIVLAZ (clazosentan) and all intellectual property and know- how for the territory, and a co-exclusive license for daridorexant – further to the agreement in place with Mochida Pharmaceutical. The transaction also includes an option for Sosei Heptares – upon payment of separate option fees – to license cenerimod and lucerastat for the development and commercialization in the Territory.
Idorsia will supply bulk tablet of PIVLAZ and daridorexant to Sosei Heptares. In addition, there will be transition service agreements (TSA) between Idorsia and Sosei Heptares mainly for regulatory/filing activities, clinical development, CMC (Chemistry, Manufacturing and Controls), and IT.
Idorsia has granted Sosei Heptares a right of first negotiation and right of first refusal on certain pipeline assets for the Territory showing a clear commitment from Idorsia to continue to work with Sosei Heptares as a preferred partner.
Territory: Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam.
Notes to the editor
About Sosei Heptares
Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world- class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions.
Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region.
Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda.
Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit Home - Sosei Heptares
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,300 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41588441010
investor.relations@idorsia.com • media.relations@idorsia.com • www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF
Release
July 20, 2023
Ad hoc announcement pursuant to Art. 53 LR
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
Allschwil, Switzerland – July 20, 2023
Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex- China) region (“Territory”), including assignment of PIVLAZ (clazosentan) and license rights to daridorexant in those territories, to Sosei Group Corporation (TSE: 4565; ‘Sosei Heptares’) for a total consideration of CHF 400 million.
Jean-Paul Clozel, Chief Executive Officer of Idorsia, commented:
“Dr Satoshi Tanaka and his team in Idorsia Japan have consistently demonstrated their ability to deliver high-quality clinical development studies, most recently reporting positive Phase 3 results with daridorexant. They also developed, registered, and successfully brought PIVLAZ to a specialty market, serving over 5’000 patients with a rare form of stroke in the first year alone. The excellence displayed by the organization has been recognized by Sosei, hence a deal that creates value for both companies. I’m particularly happy that we are maintaining our relationships to the team and our ability to reach patients in the territory with our pipeline products.”
Chris Cargill, President, and Chief Executive Officer of Sosei Heptares, commented:
“We have patiently and diligently been searching for the right opportunity to accelerate our mission to deliver life-changing new medicines to patients. This transaction with Idorsia is truly transformational and achieves one of our key strategic objectives, establishing Sosei Heptares as a fully integrated Japan-focused pharmaceutical business, with growing commercial sales and an expected new product launch next year. The addition of a highly experienced clinical development and entrepreneurial commercial team in Japan led by Dr Satoshi Tanaka, one of the country’s most successful drug developers in recent times, fast-tracks our vision to become one of Japan’s global biopharmaceutical champions.”
About the transaction
The transaction includes the acquisition by Sosei Heptares of Idorsia’s affiliates in Japan and South Korea, the assignment of the license for PIVLAZ (clazosentan) and all intellectual property and know- how for the territory, and a co-exclusive license for daridorexant – further to the agreement in place with Mochida Pharmaceutical. The transaction also includes an option for Sosei Heptares – upon payment of separate option fees – to license cenerimod and lucerastat for the development and commercialization in the Territory.
Idorsia will supply bulk tablet of PIVLAZ and daridorexant to Sosei Heptares. In addition, there will be transition service agreements (TSA) between Idorsia and Sosei Heptares mainly for regulatory/filing activities, clinical development, CMC (Chemistry, Manufacturing and Controls), and IT.
Idorsia has granted Sosei Heptares a right of first negotiation and right of first refusal on certain pipeline assets for the Territory showing a clear commitment from Idorsia to continue to work with Sosei Heptares as a preferred partner.
Territory: Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam.
Notes to the editor
About Sosei Heptares
Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world- class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions.
Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region.
Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda.
Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit Home - Sosei Heptares
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,300 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41588441010
investor.relations@idorsia.com • media.relations@idorsia.com • www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF
anonymous
Guest
anonymous
Guest
Release
July 20, 2023
Ad hoc announcement pursuant to Art. 53 LR
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
Allschwil, Switzerland – July 20, 2023
Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex- China) region (“Territory”), including assignment of PIVLAZ (clazosentan) and license rights to daridorexant in those territories, to Sosei Group Corporation (TSE: 4565; ‘Sosei Heptares’) for a total consideration of CHF 400 million.
Jean-Paul Clozel, Chief Executive Officer of Idorsia, commented:
“Dr Satoshi Tanaka and his team in Idorsia Japan have consistently demonstrated their ability to deliver high-quality clinical development studies, most recently reporting positive Phase 3 results with daridorexant. They also developed, registered, and successfully brought PIVLAZ to a specialty market, serving over 5’000 patients with a rare form of stroke in the first year alone. The excellence displayed by the organization has been recognized by Sosei, hence a deal that creates value for both companies. I’m particularly happy that we are maintaining our relationships to the team and our ability to reach patients in the territory with our pipeline products.”
Chris Cargill, President, and Chief Executive Officer of Sosei Heptares, commented:
“We have patiently and diligently been searching for the right opportunity to accelerate our mission to deliver life-changing new medicines to patients. This transaction with Idorsia is truly transformational and achieves one of our key strategic objectives, establishing Sosei Heptares as a fully integrated Japan-focused pharmaceutical business, with growing commercial sales and an expected new product launch next year. The addition of a highly experienced clinical development and entrepreneurial commercial team in Japan led by Dr Satoshi Tanaka, one of the country’s most successful drug developers in recent times, fast-tracks our vision to become one of Japan’s global biopharmaceutical champions.”
About the transaction
The transaction includes the acquisition by Sosei Heptares of Idorsia’s affiliates in Japan and South Korea, the assignment of the license for PIVLAZ (clazosentan) and all intellectual property and know- how for the territory, and a co-exclusive license for daridorexant – further to the agreement in place with Mochida Pharmaceutical. The transaction also includes an option for Sosei Heptares – upon payment of separate option fees – to license cenerimod and lucerastat for the development and commercialization in the Territory.
Idorsia will supply bulk tablet of PIVLAZ and daridorexant to Sosei Heptares. In addition, there will be transition service agreements (TSA) between Idorsia and Sosei Heptares mainly for regulatory/filing activities, clinical development, CMC (Chemistry, Manufacturing and Controls), and IT.
Idorsia has granted Sosei Heptares a right of first negotiation and right of first refusal on certain pipeline assets for the Territory showing a clear commitment from Idorsia to continue to work with Sosei Heptares as a preferred partner.
Territory: Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam.
Notes to the editor
About Sosei Heptares
Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world- class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions.
Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region.
Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda.
Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit Home - Sosei Heptares
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,300 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41588441010
investor.relations@idorsia.com • media.relations@idorsia.com • www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF
July 20, 2023
Ad hoc announcement pursuant to Art. 53 LR
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF 400 million
Allschwil, Switzerland – July 20, 2023
Idorsia Ltd (SIX: IDIA) today announced the sale of its operating businesses in the Asia Pacific (ex- China) region (“Territory”), including assignment of PIVLAZ (clazosentan) and license rights to daridorexant in those territories, to Sosei Group Corporation (TSE: 4565; ‘Sosei Heptares’) for a total consideration of CHF 400 million.
Jean-Paul Clozel, Chief Executive Officer of Idorsia, commented:
“Dr Satoshi Tanaka and his team in Idorsia Japan have consistently demonstrated their ability to deliver high-quality clinical development studies, most recently reporting positive Phase 3 results with daridorexant. They also developed, registered, and successfully brought PIVLAZ to a specialty market, serving over 5’000 patients with a rare form of stroke in the first year alone. The excellence displayed by the organization has been recognized by Sosei, hence a deal that creates value for both companies. I’m particularly happy that we are maintaining our relationships to the team and our ability to reach patients in the territory with our pipeline products.”
Chris Cargill, President, and Chief Executive Officer of Sosei Heptares, commented:
“We have patiently and diligently been searching for the right opportunity to accelerate our mission to deliver life-changing new medicines to patients. This transaction with Idorsia is truly transformational and achieves one of our key strategic objectives, establishing Sosei Heptares as a fully integrated Japan-focused pharmaceutical business, with growing commercial sales and an expected new product launch next year. The addition of a highly experienced clinical development and entrepreneurial commercial team in Japan led by Dr Satoshi Tanaka, one of the country’s most successful drug developers in recent times, fast-tracks our vision to become one of Japan’s global biopharmaceutical champions.”
About the transaction
The transaction includes the acquisition by Sosei Heptares of Idorsia’s affiliates in Japan and South Korea, the assignment of the license for PIVLAZ (clazosentan) and all intellectual property and know- how for the territory, and a co-exclusive license for daridorexant – further to the agreement in place with Mochida Pharmaceutical. The transaction also includes an option for Sosei Heptares – upon payment of separate option fees – to license cenerimod and lucerastat for the development and commercialization in the Territory.
Idorsia will supply bulk tablet of PIVLAZ and daridorexant to Sosei Heptares. In addition, there will be transition service agreements (TSA) between Idorsia and Sosei Heptares mainly for regulatory/filing activities, clinical development, CMC (Chemistry, Manufacturing and Controls), and IT.
Idorsia has granted Sosei Heptares a right of first negotiation and right of first refusal on certain pipeline assets for the Territory showing a clear commitment from Idorsia to continue to work with Sosei Heptares as a preferred partner.
Territory: Australia, Brunei, Cambodia, Indonesia, Japan, Laos, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Taiwan, and Vietnam.
Notes to the editor
About Sosei Heptares
Sosei Heptares is a fully integrated biopharmaceutical company focused on bringing life-changing medicines based on world- class science to patients globally. Our vision is to become one of Japan’s global biopharmaceutical champions.
Sosei Heptares has a leading development capability and a profitable and growing commercial operation in Japan, which it intends to expand into additional selected markets in the Asia-Pacific region.
Sosei Heptares is advancing a broad and deep pipeline of novel medicines created using its world-leading GPCR-targeted StaR® technology and structure-based drug design platform across multiple therapeutic areas, including neurology, immunology, gastroenterology, and inflammatory diseases.
In addition, we have leveraged our unique discovery and development capabilities to establish multiple value-generating partnerships with world-leading biopharmaceutical companies, including AbbVie, Genentech (Roche), GSK, Lilly, Neurocrine Biosciences, Novartis, Pfizer, Sanofi and Takeda.
Sosei Heptares is headquartered in Tokyo, Japan with corporate and R&D facilities in London and Cambridge, UK.
“Sosei Heptares” is the corporate brand and trademark of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565). Sosei, Heptares, the logo and StaR® are trademarks of Sosei Group companies. For more information, please visit Home - Sosei Heptares
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, and commercial operations in Europe, Japan, and the US – the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,300 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil +41588441010
investor.relations@idorsia.com • media.relations@idorsia.com • www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Idorsia sells its Asia Pacific (ex-China) operations – including select license rights to products – to Sosei Heptares for a total consideration of CHF
anonymous
Guest
anonymous
Guest
What’s your point? How does selling to Asia affect the US?
anonymous
Guest
anonymous
Guest
Fuck, you’re dumb. 8:10 is 18 people. You meant 8 out of 10 or 8:2 or 4:1 or 2:8 or 1:4. Either way, you’re an idiot. Or do you use moron statistics and you actually meant an n of 18?8:10= 4 : 5 , not 4:1. Seems to me you’re the elementary minded soul, probably in exponentially more ways than just math.
8:10 also means 8 out of 10 individuals.
Or, it could mean 4 out of 5. But NOT 4:1
Either way, you are wrong.
Go back to selling your 35mg Quviviq. That’s your mentality.
anonymous
Guest
anonymous
Guest
Fuck, you’re dumb. 8:10 is 18 people. You meant 8 out of 10 or 8:2 or 4:1 or 2:8 or 1:4. Either way, you’re an idiot. Or do you use moron statistics and you actually meant an n of 18?
Thinking they meant 8 out of 10, when simplified is also 4 out of 5. 80% either way.
Now go back to your blankie, calming medication, or therapy. Whatever works best for you to help you not dwell on this. It’s all gonna be ok. The men in white jackets are there to assist you.
anonymous
Guest
anonymous
Guest
What’s your point? How does selling to Asia affect the US?
because the founders in Switzerland said they had no interest in selling. Then they sold Actelion product rights to Jansen of JnJ. (The ones Jansen would take anyway; they turned down a lot of the “amazing” idorsia pipeline.)
And now, Idorsia is selling again.
If your manager believes the look-aid that Idorsia isn’t looking to sell in USA too, then they are rather dim. Or they are just bold face lying to you. Look how many sales directors and other division leaders from Idorsia have left in the past several months.
The writing is on the wall.
anonymous
Guest
anonymous
Guest
Thanks for the assist, Captain Sav-a-Moron. They were still wrong. Stick to planning mocha pump shots in your routing, pretend rep.Thinking they meant 8 out of 10, when simplified is also 4 out of 5. 80% either way.
Now go back to your blankie, calming medication, or therapy. Whatever works best for you to help you not dwell on this. It’s all gonna be ok. The men in white jackets are there to assist you.
anonymous
Guest
anonymous
Guest
So what does all this mean for the Syneos contract sales force selling Quviviq? You are all contract employees vs. full-time employees.
anonymous
Guest
anonymous
Guest
They better not touch training. What will they do without us??